1. Home
  2. MFIN vs IPHA Comparison

MFIN vs IPHA Comparison

Compare MFIN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medallion Financial Corp.

MFIN

Medallion Financial Corp.

HOLD

Current Price

$11.86

Market Cap

273.7M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.58

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MFIN
IPHA
Founded
1995
1999
Country
United States
France
Employees
179
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.7M
165.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MFIN
IPHA
Price
$11.86
$1.58
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
★ $11.00
$6.67
AVG Volume (30 Days)
★ 56.7K
45.3K
Earning Date
10-28-2026
09-17-2026
Dividend Yield
★ 4.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
$7.57
$143.06
P/E Ratio
$6.21
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.85
$1.18
52 Week High
$12.26
$2.71

Technical Indicators

Market Signals
Indicator
MFIN
IPHA
Relative Strength Index (RSI) 49.09 29.65
Support Level $11.39 $1.34
Resistance Level $12.26 $1.57
Average True Range (ATR) 0.28 0.11
MACD -0.06 -0.03
Stochastic Oscillator 49.03 0.76

Price Performance

Historical Comparison
MFIN
IPHA

About MFIN Medallion Financial Corp.

Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: